



(11)

EP 3 298 134 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):

C12N 9/22 ^(2006.01) **C12N 15/00** ^(2006.01)
A61P 27/00 ^(2006.01) **A61P 21/00** ^(2006.01)
A61P 25/00 ^(2006.01) **A61P 3/00** ^(2006.01)

(48) Corrigendum issued on:

21.06.2023 Bulletin 2023/25

(52) Cooperative Patent Classification (CPC):
(C-Sets available)

A61K 38/465; A61K 31/7088; A61K 31/7105;
A61P 3/00; A61P 3/08; A61P 3/12; A61P 5/00;
A61P 7/02; A61P 7/04; A61P 7/06; A61P 9/00;
A61P 11/00; A61P 13/02; A61P 13/12;
A61P 21/00;

(Cont.)

(45) Date of publication and mention
of the grant of the patent:

10.05.2023 Bulletin 2023/19

(21) Application number: **16718840.8**

(86) International application number:

PCT/US2016/027987

(22) Date of filing: **15.04.2016**

(87) International publication number:

WO 2016/186772 (24.11.2016 Gazette 2016/47)

(54) **GENE EDITING OF DEEP INTRONIC MUTATIONS**

GEN-EDITING VON TIEFEN INTRONISCHEN MUTATIONEN

ÉDITION GÉNIQUE DE MUTATIONS INTRONIQUES PROFONDES

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(74) Representative: **Mathys & Squire**

The Shard
32 London Bridge Street
London SE1 9SG (GB)

(30) Priority: **16.05.2015 US 201562162720 P**

(56) References cited:

WO-A1-2014/204724 WO-A1-2015/070083

(43) Date of publication of application:

28.03.2018 Bulletin 2018/13

- **Levy: "Molecular Therapy Volume 23, Supplement 1, May 2015", , 27 April 2015 (2015-04-27), XP55287857, Retrieved from the Internet:
URL:<http://www.nature.com/mt/journal/v23/n1s/pdf/mt201574a.pdf> [retrieved on 2016-07-12]
-& "ASGCT 18th Annual Meeting", American Society of Gene and Cell Therapy , 27 April 2015 (2015-04-27), XP002759938, Retrieved from the Internet:
URL:<http://www.asgct.org/meetings-educational-programs/asgct-annual-meetings/archive-d-annual-meetings/2015-annual-meeting> [retrieved on 2016-07-14]**

(73) Proprietor: **Genzyme Corporation**
Cambridge, MA 02141 (US)

(72) Inventors:

- **RUAN, Guoxiang**
Bridgewater, NJ 08807 (US)
- **SCARIA, Abraham**
Bridgewater, NJ 08807 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 298 134 B8

- Dominique L Ouellet: "Deletion of GAA Repeats Expansion from the Intron 1 of the Frataxin Gene Using CRISPR/Cas9 System", , 13 May 2015 (2015-05-13), XP55288473, Retrieved from the Internet:
URL: http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_128 [retrieved on 2016-07-14]
 - Anonymous: "Addgene: CRISPR in the Lab: A Practical Guide", , 14 May 2015 (2015-05-14), XP55288205, Retrieved from the Internet:
URL: <https://web.archive.org/web/20150514045603/http://www.addgene.org/crispr/guide/> [retrieved on 2016-07-13]
 - ANN RAN F ET AL: "Genome engineering using the CRISPR-Cas9 system", NATURE PROTOCOLS, NATURE PUBLISHING GROUP, GB, vol. 8, no. 11, November 2013 (2013-11), pages 2281-2308, XP002744123, ISSN: 1754-2189, DOI: 10.1038/NPROT.2013.143 [retrieved on 2013-10-24]
 - MOORE ET AL: "CRISPR- based self-cleaving mechanism for controllable gene delivery in human cells", NUCLEIC ACIDS RESEARCH,, vol. 43, 1 January 2015 (2015-01-01), pages 1297-1303, XP002761477,
- (52) Cooperative Patent Classification (CPC): (Cont.)
 A61P 21/02; A61P 21/04; A61P 25/00;
 A61P 25/02; A61P 25/28; A61P 27/00;
 A61P 27/02; A61P 27/12; A61P 35/00;
 A61P 35/02; A61P 37/02; A61P 43/00; C12N 9/22;
 C12N 2750/14143
- C-Sets
 A61K 31/7088, A61K 2300/00;
 A61K 31/7105, A61K 2300/00;
 A61K 38/465, A61K 2300/00